JP2021519296A5 - - Google Patents

Info

Publication number
JP2021519296A5
JP2021519296A5 JP2020551798A JP2020551798A JP2021519296A5 JP 2021519296 A5 JP2021519296 A5 JP 2021519296A5 JP 2020551798 A JP2020551798 A JP 2020551798A JP 2020551798 A JP2020551798 A JP 2020551798A JP 2021519296 A5 JP2021519296 A5 JP 2021519296A5
Authority
JP
Japan
Prior art keywords
cancer
disorder
pharmaceutical composition
composition according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020551798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519296A (ja
JP7813099B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024603 external-priority patent/WO2019191444A1/en
Publication of JP2021519296A publication Critical patent/JP2021519296A/ja
Publication of JP2021519296A5 publication Critical patent/JP2021519296A5/ja
Application granted granted Critical
Publication of JP7813099B2 publication Critical patent/JP7813099B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551798A 2018-03-28 2019-03-28 治療用物質を標的送達するためのエキソソームの使用法 Active JP7813099B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649057P 2018-03-28 2018-03-28
US62/649,057 2018-03-28
PCT/US2019/024603 WO2019191444A1 (en) 2018-03-28 2019-03-28 Use of exosomes for targeted delivery of therapeutic agents

Publications (3)

Publication Number Publication Date
JP2021519296A JP2021519296A (ja) 2021-08-10
JP2021519296A5 true JP2021519296A5 (cg-RX-API-DMAC7.html) 2022-04-04
JP7813099B2 JP7813099B2 (ja) 2026-02-12

Family

ID=68060505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551798A Active JP7813099B2 (ja) 2018-03-28 2019-03-28 治療用物質を標的送達するためのエキソソームの使用法

Country Status (7)

Country Link
EP (1) EP3773747A4 (cg-RX-API-DMAC7.html)
JP (1) JP7813099B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200136978A (cg-RX-API-DMAC7.html)
CN (1) CN112533643A (cg-RX-API-DMAC7.html)
AU (1) AU2019243179B2 (cg-RX-API-DMAC7.html)
CA (1) CA3095136A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019191444A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095134A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
IT201900007785A1 (it) * 2019-05-31 2020-12-01 Univ Degli Studi Milano Vescicole extracellulari per veicolare farmaci terapeutici o diagnostici
US20230013636A1 (en) * 2019-12-05 2023-01-19 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases with fibrosis
WO2021119552A1 (en) 2019-12-13 2021-06-17 Lawrence Livermore National Security, Llc Nanotube-vesicle compositions and uses thereof
CN114081960A (zh) * 2021-11-17 2022-02-25 中国人民解放军空军军医大学 一种前列腺癌分子靶向系统及其构建方法和应用
CN114774471A (zh) * 2022-05-10 2022-07-22 厦门星际诺康细胞科技有限公司 一种呈现il27稳转细胞及其构建方法、呈现il27工程化外泌体及其制备方法和应用
KR20250171535A (ko) * 2024-05-29 2025-12-09 사회복지법인 삼성생명공익재단 전기천공법을 이용한 상처치유용 세포외 소포체의 제조방법
WO2026002276A1 (zh) * 2024-06-28 2026-01-02 艾码生物科技(南京)有限公司 靶向tgfb的rna干扰方法、核酸及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US9085778B2 (en) * 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
GB201121069D0 (en) * 2011-12-07 2012-01-18 Isis Innovation Delivery system
EP3415627A1 (en) * 2012-11-13 2018-12-19 Codiak BioSciences, Inc. Delivery of therapeutic agent
MX2015004626A (es) * 2012-11-29 2015-07-14 Yeda Res & Dev Metodos para prevenir metastasis de tumor, tratar y pronosticar cancer e identificar agentes que son inhibidores putativos de metastasis.
WO2015085096A1 (en) * 2013-12-04 2015-06-11 Board Of Regents, The University Of Texas System Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
EA201890006A1 (ru) * 2015-06-10 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Применение экзосом для лечения болезни
WO2017117585A1 (en) * 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
TWI601741B (zh) * 2016-07-11 2017-10-11 財團法人國家衛生研究院 利用前列腺素受體ep4-拮抗劑誘導幹細胞製造含有高囊泡含物之外泌體囊泡的方法及其應用

Similar Documents

Publication Publication Date Title
Li et al. Blockage of transferred exosome‐shuttled miR‐494 inhibits melanoma growth and metastasis
Lee et al. The long non-coding RNA HOTAIR increases tumour growth and invasion in cervical cancer by targeting the Notch pathway
Zukiel et al. Suppression of human brain tumor with interference RNA specific for tenascin-C
Guo et al. Interleukin-17 promotes migration and invasion of human cancer cells through upregulation of MTA1 expression
Zhou et al. Silencing collapsin response mediator protein-2 reprograms macrophage phenotype and improves infarct healing in experimental myocardial infarction model
KR102599712B1 (ko) C/EBP 알파 saRNA 조성물 및 사용 방법
Xiao et al. MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling
Beck et al. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression
Fujita et al. A novel platform to enable inhaled naked RNAi medicine for lung cancer
Deng et al. Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo.
JP7069013B2 (ja) 望ましくない細胞増殖に関係する疾患の処置のための薬剤
Mirna et al. A new player in the game: treatment with antagomiR-21a-5p significantly attenuates histological and echocardiographic effects of experimental autoimmune myocarditis
Kurrikoff et al. Effective lung-targeted RNAi in mice with peptide-based delivery of nucleic acid
CN107828888B (zh) 环状RNA circ-PTPRA的用途
JP2024502295A5 (cg-RX-API-DMAC7.html)
Wang et al. shRNA-mediated silencing of Y-box binding protein-1 (YB-1) suppresses growth of neuroblastoma cell SH-SY5Y in vitro and in vivo
WO2019165848A1 (zh) 一种由NF-κB启动的肿瘤细胞特异效应基因表达载体及其表达产物和应用
JP6768979B2 (ja) Hsp47の阻害物質を用いた、がん転移抑制
Yoshikawa et al. Intraperitoneal administration of synthetic microRNA-214 elicits tumor suppression in an intraperitoneal dissemination mouse model of canine hemangiosarcoma
CN113151280A (zh) 一种小分子非编码rna及宿主基因在胃癌诊断及治疗的应用
CN104531709A (zh) 抑制肿瘤生长与转移的siRNA双干扰组合物及其应用
Omidi et al. Aptamers as smart ligands for the development of cancer-targeting nanocarriers
CN109453385B (zh) 一种用于治疗癌症的组合物及其应用
CN101433724A (zh) Akt2-siRNA融合表达载体在制备抑制人乳腺癌细胞转移药物中的应用
CN116162656B (zh) 基因组合及其表达载体和用途